This is a phase 1b prospective, single arm, open-label trial determining the efficacy and feasibility of using a ctDNA assay (test) result to help guide neoadjuvant chemotherapy in subjects with Stage IB, II or Stage III adenocarcinoma of the stomach or gastroesophageal junction (GEA).

Start Date01 Feb 2025

Sponsor / Collaborator

University of California, Irvine

[+1]

NCT06227065 / Not yet recruitingPhase 2IIT

Precise Neoadjuvant Chemoresection of Low Grade NMIBC Guided by Drug Screens in Patient Derived Organoidst: A Single Center, Open-label, Phase II Trial

Based on the unmet clinical need to reduce invasiveness of treatment of low grade NMIBC, the investigators conduct this prospective, open label, single arm and single center phase II trial. The investigators aim to use drug screens in PDOs to guide neoadjuvant intravesical instillation therapy with either Epirubicin, Mitomycin C, Gemcitabine or Docetaxel to achieve chemoresection NMIBC.

Start Date01 Oct 2024

Sponsor / Collaborator

University of Bern

[+1]

100 Clinical Results associated with Docetaxel

100 Translational Medicine associated with Docetaxel

100 Patents (Medical) associated with Docetaxel

17,490

Literatures (Medical) associated with Docetaxel

01 Dec 2024·Pharmaceutical biology

Comparative efficacy and safety of Chinese medicine injections as an adjunctive therapy for cervical cancer in Chinese patients: a network meta-analysis.

Review

Author: Fei Ma ; Qun Wang ; Di Zhang ; Zihong Wang ; Hui Xie ; Xianghong Liu ; Hongxing Zhang ; Haiyan Song ; Shiguang Sun

CONTEXT:

Chinese medicine injections (CMIs) are widely used as adjuvant therapy for cervical cancer in China. However, the effectiveness of different types of CMIs remains uncertain.

OBJECTIVE:

To assess the effectiveness and safety of CMIs when used in conjunction with radiotherapy (RT) or concurrent chemoradiotherapy (CCRT), particularly in combination with cisplatin (DDP), docetaxel plus cisplatin (DP), and paclitaxel plus cisplatin (TP).

MATERIALS AND METHODS:

Randomized controlled trials (RCTs) were searched in databases including CNKI, WanFang, VIP, SinoMed, PubMed, Cochrane Library, Embase, and Web of Science from inception to September 2023. We calculated the risk ratio with a 95% confidence interval and the surface under the cumulative ranking area curve (SUCRA) for the clinical efficacy rate (CER), the efficacy rate by Karnofsky Performance Status (KPS), and the rates of leukopenia reduction (LRR) and gastrointestinal reactions (GRR).

RESULTS:

Forty-seven RCTs were included, including nine CMI types: Aidi, Fufangkushen, Huangqi, Kangai (KA), Kanglaite (KLT), Renshenduotang, Shenqifuzheng (SQFZ), Shenmai (SM), and Yadanzi. KLT and KA were likely optimal choices with radiotherapy for CER and KPS, respectively. KA and KLT were optimal choices with RT + DDP for CER and GRR, respectively. KLT was the likely optimal choice with RT + DP for CER and KA for both KPS and GRR. SM and SQFZ were the likely optimal choices with RT + TP for CER and LRR, respectively.

CONCLUSIONS:

The optimal recommendation depends on whether CMIs are used with radiotherapy or concurrent chemoradiotherapy. More high-quality RCTs are needed to confirm further and update the existing evidence.

01 Mar 2024·European urology open science

Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study.

Article

Author: Chiara Casadei ; Emanuela Scarpi ; Vincenza Conteduca ; Giorgia Gurioli ; Maria Concetta Cursano ; Nicole Brighi ; Cristian Lolli ; Giuseppe Schepisi ; Umberto Basso ; Giuseppe Fornarini ; Sara Bleve ; Alberto Farolfi ; Amelia Altavilla ; Salvatore Luca Burgio ; Emilio Francesco Giunta ; Caterina Gianni ; Alessia Filograna ; Paola Ulivi ; David Olmos ; Elena Castro ; Ugo De Giorgi

Background:

The prevalence of pathogenic germline mutations in DNA damage repair (gDDR) genes in the Italian population is unknown.

Objective:

In this prospective multicenter cohort study, we evaluated the prevalence of gDDR alterations in the Italian population affected by metastatic prostate cancer (mPCa) and analyzed the impact on response to therapy, survival, and time to castration resistance.

Design setting and participants:

In an observational prospective trial, 300 consecutive Italian mPCa patients, enrolled in the Meet-Uro-10 trial from three academic Italian centers, were recruited between 2017 and 2019 and were screened for gDDR mutations in 107 genes.

Outcome measurements and statistical analysis:

The primary endpoint was to assess the prevalence of gDDR mutations in the Italian population of patients with mPCa. The secondary endpoints included the association of gDDR subgroups with metastatic onset, Gleason score, and time to castration resistance.

Results and limitations:

We identified 297 valuable patients. Forty-six patients had a pathogenic/likely pathogenic variant (15.5%, 95% confidence interval: 11.4-19.6): the more frequent was gBRCA2 found in nine cases (3%), followed by gATM in five cases (1.7%). In patients without mutations, longer median overall survival was observed with the sequence docetaxel-androgen receptor signaling inhibitor (ARSI) than with the sequence ARSI-docetaxel (87.9 vs 42 mo, p = 0.0001). In a univariate analysis, the median time to castration resistance in gDDR mutated patients was 19.8 mo, versus 23.7 mo in no mutated patients (p = 0.024). There were no associations of gDDR subgroups with metastatic onset and Gleason score ≥8. In our cohort, variants of unknown significance in gDDR genes were found in 80 patients and might have a prognostic relevance.

Conclusions:

The study reported the prevalence of gDDR in the Italian population. The presence of gBRCA2 mutations correlates with a shorter time to the onset of castration resistance disease.

Patient summary:

The prevalence of gBRCA2 in the Italian population is 3%, which is similar to that in the Spanish population, identifying similarities between people of the Western Mediterranean area.

01 Mar 2024·Carbohydrate polymers

Functional structural domain synthesis of anti-pancreatic carcinoma pectin-like polysaccharide RN1

Article

Author: Cai, Deqin ; He, Fei ; Wu, Shengjie ; Wang, Zixuan ; Bian, Ya ; Wen, Chang ; Ding, Kan

The great structural and functional diversity supports polysaccharides as favorable candidates for new drug development. Previously we reported that a drug candidate pectin-like natural polysaccharide, RN1 might target galectin-3 (Gal-3) to impede pancreatic cancer cell growth in vivo. However, the quality control of polysaccharide-based drug research faces great challenges due to the heterogeneity. A potential solution is to synthesize structurally identified subfragments of this polysaccharide as alternatives. In this work, we took RN1 as an example, and synthesized five subfragments derived from the putative repeating units of RN1. Among them, pentasaccharide 4 showed an approximative binding affinity to Gal-3 in vitro, as well as an antiproliferative activity against pancreatic BxPC-3 cells comparable to that of RN1. Further, we scaled up pentasaccharide 4 to gram-scale in an efficient synthetic route with a 6.9 % yield from D-galactose. Importantly, pentasaccharide 4 significantly suppressed the growth of pancreatic tumor in vivo. Based on the mechanism complementarity of galactin-3 inhibitor and docetaxel, the combination administration of pentasaccharide 4 and docetaxel afforded better result. The result suggested pentasaccharide 4 was one of the functional structural domains of polysaccharide RN1 and might be a leading compound for anti-pancreatic cancer new drug development.

542

News (Medical) associated with Docetaxel

03 Apr 2024

·www.biospace.com

MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures

Early interim safety data from Phase 2 TAMARACK study, including comparison to retrospective analysis from Phase 1 study,as submitted in ASCO abstract Company plans to provide updated interim data, including safety and preliminary efficacy, by May 31 Company plans to provide additional clinical data – including rPFS – in the Fall of 2024 ROCKVILLE, MD, April 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc., (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on the Phase 2 TAMARACK study of vobramitamab duocarmazine (vobra duo, previously known as MGC018) in patients with metastatic castration-resistant prostate cancer (mCRPC). As previously disclosed, safety data from the Company’s ongoing TAMARACK Phase 2 study was submitted in early February to the American Society of Clinical Oncology (ASCO) for presentation at the upcoming Annual Meeting that begins May 31. The abstract containing this early interim data, based on a January 4, 2024 data cut-off, was not accepted. The submitted abstract is provided below. “While the TAMARACK data will not be presented at the ASCO Annual Meeting, we intend to maintain our previously disclosed plan to share further TAMARACK interim data, including updated safety and preliminary efficacy, by the end of May,” said Scott Koenig, M.D., Ph.D., President and Chief Executive Officer. “This updated information will be based upon a future data cut-off. In addition, we still anticipate presenting updated clinical data – including radiographic progression-free survival, or rPFS, the study’s primary endpoint – in the Fall of 2024.” Abstract as submitted on February 6, 2024: “Title Vobramitamab duocarmazine (vobra duo), a B7-H3 directed antibody drug conjugate (ADC) in metastatic castration resistant prostate cancer (mCRPC): Early data from the Phase 2 TAMARACK study. Background Vobra duo (MGC018) is an ADC with a duocarmycin-based DNA-alkylating payload. Vobra duo targets B7-H3, which is highly expressed in multiple tumor types including prostate cancer and has limited expression in normal tissue. Phase 1 testing (NCT03729596) of vobra duo at 3.0 mg/kg Q3W demonstrated anti-tumor activity in mCRPC, although adverse events resulted in high rates of dose modifications and early treatment discontinuation. Lowering the starting dose may improve tolerability, extend treatment duration, and enhance effectiveness. Methods TAMARACK is an ongoing randomized, open-label, Phase 2 dose selection study assessing the efficacy, safety, and tolerability of two dose levels of vobra duo (2.0 mg/kg and 2.7 mg/kg IV Q4W). The study enrolled patients (pts) with mCRPC previously treated with abiraterone, enzalutamide, or apalutamide; prior docetaxel was allowed. The primary endpoint is investigator-assessed PFS at 6 months. Results At data cutoff (Jan 4, 2024), 182 pts with mCRPC enrolled on TAMARACK, of which 177 received vobra duo. Enrolled pts were 46 to 89 years of age (median 70.5) with ECOG performance status ≤ 2. Thirty (16.5%) had visceral disease at baseline, 109 (59.9%) had RECIST-evaluable disease, and 98 (53.8%) received prior docetaxel. At this early data cut, pts have received a median of 3 (range 1 to 7) cycles of vobra duo; treatment is ongoing in 156 (85.7%). A summary of treatment-emergent adverse events (TEAEs) is presented below. Vobra duo 2.0 mg/kg (n=91) Vobra duo 2.7 mg/kg (n=86) Any TEAE 85 (93.4%) 82 (95.3%) TEAE Grade ≥ 3 23 (25.3%) 27 (31.4%) Serious AE 11 (12.1%) 17 (19.8%) Drug Interruption due to AE 10 (11.0%) 16 (18.6%) Drug Discontinuation due to AE 4 (4.4%) 2 (2.3%) Fatal AE 0 0 The most common (≥10%) TEAEs regardless of dose were asthenia (40.7%), nausea (27.7%), fatigue (20.3%), decreased appetite (19.2%), anemia (17.5%), constipation (16.4%), diarrhea (14.7%), headache (13.0%), neutropenia (12.4%), and peripheral edema (10.7%). In the subset (n = 95) of TAMARACK pts on treatment for ≥ 12 weeks or who discontinued study treatment within 12 weeks, TEAEs led to drug interruption in 12 (12.6%) and discontinuation in 5 (5.3%) pts. This compares favorably to the rate of drug interruption (58.5%) and discontinuation (14.6%) observed at 12 weeks in pts with mCRPC who received vobra duo at 3.0 mg/kg Q3W on the Phase 1 study. Following the pre-specified interim analysis for futility on both arms, the IDMC recommended continuing the study as planned without modification. Conclusions Preliminary safety data from TAMARACK suggest that reducing the dose and frequency of vobra duo improves its safety and tolerability in men with mCRPC. The authors anticipate sharing preliminary efficacy data and updated safety data at the conference. Clinical trial information: NCT05551117.” MacroGenics would like to thank the abstract authors, including: Johann S. De Bono, Carole Helissey, Karim Fizazi, Eric Voog, Pablo Maroto-Rey, Guilhem Roubaud, Emmanuel S. Antonarakis, Shahneen Sandhu, Neal D. Shore, Raffaele Ratta, Begoña Pérez Valderrama, Christof Vulsteke, Galina Marr, Ashley Ward, Enxu Zhao, Josep M. Piulats, on behalf of the TAMARACK Investigators. About MacroGenics, Inc. MacroGenics (the Company) is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at . MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc. Cautionary Note on Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for MacroGenics (“Company”), including statements about the Company’s strategy, future operations, clinical development of the Company’s therapeutic candidates, including initiation and enrollment in clinical trials, expected timing of results from clinical trials, discussions with regulatory agencies, commercial prospects of or product revenues from MARGENZA and the Company’s product candidates, if approved, manufacturing services revenue, milestone or opt-in payments from the Company’s collaborators, the Company’s anticipated milestones and future expectations and plans and prospects for the Company, as well as future global net sales of TZIELD and the Company’s ability to achieve the milestone payments set forth under the terms of the agreement with DRI (or its successors or assigns with respect to such agreement), and other statements containing the words “subject to”, "believe", “anticipate”, “plan”, “expect”, “intend”, “estimate”, “potential,” “project”, “may”, “will”, “should”, “would”, “could”, “can”, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks that TZIELD, vobramitamab duocarmazine, lorigerlimab, ZYNYZ, MARGENZA or any other product candidate’s revenue, expenses and costs may not be as expected, risks relating to TZIELD, vobramitamab duocarmazine, lorigerlimab, ZYNYZ, MARGENZA or any other product candidate’s market acceptance, competition, reimbursement and regulatory actions; our ability to provide manufacturing services to our customers; the uncertainties inherent in the initiation and enrollment of future clinical trials; the availability of financing to fund the internal development of our product candidates; expectations of expanding ongoing clinical trials; availability and timing of data from ongoing clinical trials; expectations for the timing and steps required in the regulatory review process; expectations for regulatory approvals; expectations of future milestone payments; the impact of competitive products; our ability to enter into agreements with strategic partners and other matters that could affect the availability or commercial potential of the Company's product candidates; business, economic or political disruptions due to catastrophes or other events, including natural disasters, terrorist attacks, civil unrest and actual or threatened armed conflict, or public health crises such as the novel coronavirus (referred to as COVID-19 pandemic); and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof. CONTACTS: Jim Karrels, Senior Vice President, CFO 1-301-251-5172 info@macrogenics.com

Clinical ResultASCOPhase 1Phase 2ADC

29 Mar 2024

·firstwordpharma.com

Krazati nearer to full FDA nod after confirmatory lung cancer study win

Bristol Myers Squibb is a step closer in its quest for full FDA approval of Krazati (adagrasib) in non-small-cell lung cancer (NSCLC), announcing that the KRAS blocker met the primary endpoint of progression-free survival (PFS) in a confirmatory trial.The drug, originally developed by Mirati Therapeutics, was granted an accelerated approval in 2022 for second-line KRAS-mutated NSCLC based on results from the single-arm mid-stage KRYSTAL-1 trial demonstrating a 43% objective response rate (ORR).The company now says that the pivotal Phase III KRYSTAL-12 study, which included 453 patients, showed a significant benefit with Krazati on time to disease progression or death when used as a second- or later-line treatment for locally advanced or metastatic NSCLC that carries a KRASG12C mutation. The drug was compared to standard-of-care chemotherapy.Study ongoing to assess OSKrazati also achieved the secondary goal of ORR in KRYSTAL-12, although Bristol Myers Squibb said the trial remains ongoing to assess the additional key secondary endpoint of overall survival (OS). There were no new safety signals and the safety results were consistent with the drug's known profile, it added."We are encouraged by the results from KRYSTAL-12," said Abderrahim Oukessou, global programme lead for Krazati at Bristol Myers Squibb, which got hold of the drug through its $5.8-billion takeout of Mirati that closed at the start of the year. A detailed analysis of the trial is underway, with results to be shared at an upcoming medical conference and with health authorities.EU regulators approved Krazati in January for second-line NSCLC after reconsidering their initial intention of rejecting the drug.Pulling ahead?The KRYSTAL-12 top-line readout comes on the heels of Amgen's setback with rival KRAS inhibitor Lumakras (sotorasib). The drug has also received an accelerated approval by the FDA in second-line NSCLC patients, although about 18 months before Krazati, based on ORR data from the CodeBreaK 100 study.Amgen later submitted Phase III CodeBreaK 200 results in its bid to convert that to a traditional approval. However, the FDA issued a complete response letter to Amgen in December, requesting an additional confirmatory study to prove Lumakras' benefit.While CodeBreaK 200 met its primary endpoint with a PFS benefit of 34% for Lumakras over docetaxel, that failed to sway an FDA advisory panel, which voted that the data could not be reliably interpreted. Ahead of the vote, FDA staff scientists had also suggested the survival results were "uncertain," and cast doubt on whether the study could be considered "adequate and well-controlled." For more, see Vital Signs: Do KRAS blunders weigh down targeted therapy in lung cancer?

Phase 3Clinical ResultDrug ApprovalAccelerated Approval

29 Mar 2024

·www.biopharmadive.com

Bristol Myers says KRAS drug succeeds in key trial

Dive Brief:Bristol Myers Squibbs cancer pill Krazati helped people with a certain kind of non-small cell lung cancer live longer without their disease progressing and shrank tumors at a higher rate than those given chemotherapy, the company said Thursday.The data could help Bristol Myers persuade the Food and Drug Administration to convert Krazatis conditional approval into a full clearance, potentially giving it an advantage over Amgens rival drug Lumakras. Amgens bid to gain confirmatory approval was unsuccessful, and the company has four years to complete another trial testing its pill.Both Krazati and Lumakras target tumors harboring a mutation in a gene called KRAS a long-sought goal of drugmakers. While their uptake is currently modest, both Bristol Myers and Amgen are working to expand their use into earlier lines of treatment and other types of cancer.Dive Insight:KRAS mutations are one of the most common in non-small cell lung cancer. People whose tumors are positive for the mutation have poorer prognosis than those who dont. For years, developers tried and failed to come up with a targeted KRAS therapy, leading some to consider it undruggable. That changed when Amgen was able to quickly push Lumakras through clinical trials and onto the market.Yet the two drugs arent selling that quickly. Amgen reported Lumakras sales of $280 million in 2023, a slight decline from the year earlier. Krazatis original developer, Mirati Therapeutics, reported $36 million in sales through the first nine months of 2023. Bristol Myers $4.8 billion acquisition of Mirati closed in January.Under Mirati, Krazati won conditional, or accelerated, FDA approval on the basis of a trial that measured response but didnt compare Krazati to another treatment or placebo. In 112 patients who had progressed following treatment with chemotherapy and an immunotherapy like Merck & Co.s Keytruda, Krazati spurred partial remissions in 42%.In the KRYSTAL-12 trial for which Bristol Myers reported results Thursday, Krazati was compared to treatment with docetaxel in more than 400 patients. The company didn't disclose full results, but said Krazati met the studys primary goal of improving progression-free survival over docetaxel, as well as a key secondary goal of response rate. The trial is continuing so researchers can test whether the people who received Krazati will live longer overall than those given docetaxel.Because the trial is in the same population for which Krazati already has conditional approval, it probably will not expand the number of patients eligible to receive the drug. However, it could give regulators and physicians more confidence Krazati is a better choice than chemotherapy depending on how the full data looks.Bristol Myers has submitted an application to the FDA to use Krazati in combination with chemotherapy in people whose KRAS-mutated colorectal cancer has returned after treatment. The FDAs deadline decision is June 21.Also on Thursday, Bristol Myers reported negative results for a study of its immune disease drug Zeposia in Crohns disease. Along with Krazati, Zeposia is one of several drugs Bristol Myers is counting on to grow sales. '

Drug ApprovalAcquisitionImmunotherapyClinical ResultAccelerated Approval

100 Deals associated with Docetaxel

External Link

KEGG	Wiki	ATC	Drug Bank
D07866	Docetaxel	L01CD02	DB01248

R&D Status

Indication	Highest Phase	Country/Location	Organization
Castration-Resistant Prostatic Cancer	Approved	US More	Ingenus Pharmaceuticals LLC More
stomach adenocarcinoma	Approved	US More	Meridian Laboratories, Inc. More
Squamous Cell Carcinoma of Head and Neck	Approved	US More	Meridian Laboratories, Inc. More
Non-Small Cell Lung Cancer	Approved	US More	Ingenus Pharmaceuticals LLC More
Breast Cancer	Approved	US More	Ingenus Pharmaceuticals LLC More

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO_GU2024 Manual	Not Applicable	Metastatic castration-resistant prostate cancer \| \|	915	ADT (One or more TSG mutations)	(dzyijdwuaj) = vibinkkxeb jjihfqbhdp (bfynmwnrxb )	Negative	25 Jan 2024
				Docetaxel (One or more TSG mutations)	(dzyijdwuaj) = tjaqmnjolx jjihfqbhdp (bfynmwnrxb )
JCOG1109 NExT (ASCO_GI2024) Manual	Not Applicable	Esophageal Carcinoma Neoadjuvant	91	docetaxel+ cisplatin + 5-FU	(suhgufyjyg) = The most common grade 3 or 4 AEs were neutropenia (58/91, 63.7 %), diarrhea (15/91, 16.5%), and thrombosis (9/91, 9.9%), respectively. kaohiwujaf (ggulkzepfr )	Positive	18 Jan 2024
ASCO_GI2024 Manual	Not Applicable	Locally Advanced Esophageal Squamous Cell Carcinoma Neoadjuvant	33	nivolumab+docetaxel+ cisplatin+ fluorouracil	(dwvzecxsrw) = wwjhkvepqy inxikgwpei (aptrkqnfrd, 39.8 ~ 79.7) View more	Positive	18 Jan 2024
ASCO_GI2024 Manual	Not Applicable	Locally Advanced Gastric Carcinoma Neoadjuvant	38	Fluorouracil+ leucovorin+ oxaliplatin + docetaxel	(ijusxwwmjq) = uztjlozggr esxlpkfdac (jckoyqswvp, 1.0 ~ 28) View more	Negative	18 Jan 2024
NCT04547153 (ASCO_GI2024) Manual	Phase 2	Stomach Cancer First line	24	Fluorouracil +docetaxel	(nygnhfkzvq) = zdhnjnrchm bitemhaekh (cbulwsnhon, 67.3 ~ 99.4) View more	Positive	18 Jan 2024
jRCTs031180143 (JCOG1314 (MIRACLE), ASCO_GI2024) Manual	Phase 3	Esophageal Carcinoma	240	docetaxel+cisplatin+ 5-FU	(gsoxkvwrfk) = dfipqfgoce guedvkbcxm (lawwenxfzs ) View more	Negative	18 Jan 2024
				cisplatin + 5-FU	(gsoxkvwrfk) = mfqeahzxew guedvkbcxm (lawwenxfzs ) View more
NCT102799602 (ARASENS, ASCO_GU2024) Manual	Phase 3	Castration-sensitive prostate cancer	-	DarolutamiDocetaxeltaxel + ADT	(noxghzamuv) = glcgrxlhpu nqzfzddfof (rybfqipvbh, 6.54 ~ 9.14) View more	Positive	25 Jan 2024
				DarolutamidecetDocetaxelT	(noxghzamuv) = abdqmxgnsp nqzfzddfof (rybfqipvbh, 4.92 ~ 6.96) View more
CTRI/2020/03/023944 (DOC-GC, ASCO_GI2024) Manual	Phase 3	Advanced gastric carcinoma	324	modified CAPOX or modified FDocetaxeldocetaxeloxaliplatincapecitabine	(obufnlvrqc) = qpeozfxvbu heqhmkroel (pqlvqydvyv, 9.2-10.9) View more	Negative	18 Jan 2024
				5-FU+leucovorin+Oxaliplatin+Docetaxel or docetaxel+oxaliplatin+capecitabine	(obufnlvrqc) = qcmysdzdia heqhmkroel (pqlvqydvyv, 7.3-10.5) View more
ASCO_GU2024 Manual	Not Applicable	Castration-sensitive prostate cancer	297	ADT + docetaxel or abiraterone or enzalutamide (low PTEN expression)	fzkgadhtnr(hptuetrgrl): HR = 1.8 (95% CI, 1.3 - 2.4) View more	Positive	25 Jan 2024
				ADT +docetaxel or abiraterone or enzalutamide (high/medium PTEN expression)
FDA_CDER Manual	Not Applicable	HER2 Positive Breast Cancer	3,222	docetaxel and carboplatin plus trastuzumab (TCH)	(boaeicebdt) = nzjisczgcp bmeanfwlmi (nqeslkomgm ) View more	Positive	25 Apr 2024
				docetaxel plus trastuzumab (AC→TH)	(boaeicebdt) = urcvynhhkr bmeanfwlmi (nqeslkomgm ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis